最新融资！爱亿生医疗完成天使轮

Group 1 - The core viewpoint of the article highlights the recent developments and future events related to the medical technology industry, particularly focusing on Aiyisheng Medical's advancements in artificial blood vessels [1][3][4] - Aiyisheng Medical, established in 2023 and headquartered in Guangzhou, specializes in the development, production, and sales of high-end implantable medical devices, with a focus on small-diameter artificial blood vessels [3][4] - The company has formed deep collaborations with Wuhan University of Technology and domestic clinical medical experts to promote the integration of medicine and engineering, aiming to enhance the industry chain [3][4] Group 2 - Aiyisheng Medical recently completed its first clinical trial implantation of a domestically produced puncture-type artificial blood vessel, marking a significant milestone for the company [4] - The unique puncture-type design of the artificial blood vessel allows for dialysis puncture within three days post-surgery, significantly reducing patient waiting time compared to traditional artificial blood vessels, which typically require 4-8 weeks for swelling to subside [6] - The product demonstrates notable advantages in long-term patency, repeated puncture tolerance, and surgical suturing convenience, positioning it as a competitive solution in the market traditionally dominated by imported products [6]